Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study

SIMPLE SUMMARY: Pancreatic cancer is still a challenging disease, as chemotherapeutic options are limited. We present the data of a new liposomally formulated short interfering RNA, Atu027, which has antimetastatic activity. In this randomized trial, pharmacokinetics and efficacy were assessed in tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultheis, Beate, Strumberg, Dirk, Kuhlmann, Jan, Wolf, Martin, Link, Karin, Seufferlein, Thomas, Kaufmann, Joerg, Feist, Mathilde, Gebhardt, Frank, Khan, Mike, Stintzing, Sebastian, Pelzer, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693593/
https://www.ncbi.nlm.nih.gov/pubmed/33114652
http://dx.doi.org/10.3390/cancers12113130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693593/
https://www.ncbi.nlm.nih.gov/pubmed/33114652
http://dx.doi.org/10.3390/cancers12113130

Ejemplares similares